What does additional paid-in capital mean?

Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.

Polaryx Therapeutics, Inc. PLYX Additional Paid-In Capital

Additional Paid-In Capital at other companies

BioMarin PharmaceuticalsBMRN

$5.97B+3.0%

Zevra Therapeutics, Inc.ZVRA

$602.75M+7.5%

Eton Pharmaceuticals, Inc.ETON

$141.53M+5.7%

XER

Xeris Biopharma Holdings, Inc.XERS

$682.09M+5.6%

Relay Therapeutics, Inc.RLAY

$2.73B+7.6%

PVL

Palvella TherapeuticsPVLA

$383.42M+143%

Other financials

Income statement

See full

Operating income-$2.0M+61.2%

Net income-$2.5M+49.6%

EPS (diluted)-$0.05+54.5%

Balance sheet

See full

Cash & equivalents$3.1M+1,132%

Total equity$2.5M-41.5%

Total assets$3.5M—

Cash flow

See full

Operating cash flow-$2.1M-191%

Valuation

See full

Market cap$132.59M-86.9%

Returns & leverage

See full

Return on equity-1,209.8%—

Current ratio3.5×—

Where this comes from

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Polaryx Therapeutics, Inc. ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Polaryx Therapeutics, Inc. 's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Polaryx Therapeutics, Inc. 's additional paid-in capital?: Polaryx Therapeutics, Inc. (PLYX) reported additional paid-in capital of $104.66M in Q1 2026.
What does additional paid-in capital mean?: Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.